LU92114I2 - Ferumoxytol - Google Patents

Ferumoxytol

Info

Publication number
LU92114I2
LU92114I2 LU92114C LU92114C LU92114I2 LU 92114 I2 LU92114 I2 LU 92114I2 LU 92114 C LU92114 C LU 92114C LU 92114 C LU92114 C LU 92114C LU 92114 I2 LU92114 I2 LU 92114I2
Authority
LU
Luxembourg
Prior art keywords
compositions
methods
agent
ferumoxytol
agents
Prior art date
Application number
LU92114C
Other languages
English (en)
Original Assignee
Amag Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22436002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92114(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amag Pharmaceuticals Inc filed Critical Amag Pharmaceuticals Inc
Publication of LU92114I2 publication Critical patent/LU92114I2/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Iron (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Cookers (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
LU92114C 1999-04-09 2012-12-14 Ferumoxytol LU92114I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12857999P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
LU92114I2 true LU92114I2 (fr) 2013-12-14

Family

ID=22436002

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92114C LU92114I2 (fr) 1999-04-09 2012-12-14 Ferumoxytol

Country Status (11)

Country Link
US (2) US6599498B1 (fr)
EP (1) EP1169062B1 (fr)
JP (2) JP5064612B2 (fr)
AT (1) ATE446108T1 (fr)
CY (1) CY1109527T1 (fr)
DE (1) DE60043188D1 (fr)
DK (1) DK1169062T3 (fr)
ES (1) ES2334555T3 (fr)
LU (1) LU92114I2 (fr)
PT (1) PT1169062E (fr)
WO (1) WO2000061191A2 (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7169618B2 (en) * 2000-06-28 2007-01-30 Skold Technology Magnetic particles and methods of producing coated magnetic particles
DE10046514A1 (de) * 2000-09-15 2002-04-25 Diagnostikforschung Inst Verfahren zur bildlichen Darstellung und Diagnose von Thromben mittels Kernspintomographie unter Verwendung partikulärer Kontrastmittel
US6690962B2 (en) 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
AU2002220280A1 (en) * 2000-12-07 2002-06-18 Ad "Zdravlje" Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex
CN1522161A (zh) 2001-06-29 2004-08-18 �Ȱ�ά����ķ�ɷݹ�˾ 批量高压灭菌方法
AU2003207438A1 (en) 2002-01-02 2003-07-24 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060018835A1 (en) * 2004-04-02 2006-01-26 General Electric Company Nanoparticles with inorganic core and methods of using them
US20060014938A1 (en) * 2004-07-14 2006-01-19 Groman Ernest V Stable aqueous colloidal lanthanide oxides
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
EP1880228B1 (fr) 2005-05-09 2011-07-06 The General Hospital Corporation Capteurs a relaxation par eau
JP5295769B2 (ja) * 2005-08-31 2013-09-18 ティツー・バイオシステムズ・インコーポレーテッド 分析物を検出するためのｎｍｒ装置
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
EP1973575B1 (fr) 2005-12-22 2019-07-24 Visen Medical, Inc. Nanoparticules d'oxyde métallique fluorescentes biocompatibles
AU2016205002C1 (en) * 2006-01-06 2020-09-24 Vifor (International) Ag Methods and compositions for administration of iron
AU2013206429B2 (en) * 2006-01-06 2016-04-28 Vifor (International) Ag Methods and compositions for administration of iron
EP3081219A1 (fr) 2006-01-06 2016-10-19 Luitpold Pharmaceuticals, Inc. Procédés et compositions pour l'administration de fer
NO329127B1 (no) * 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
US8368402B2 (en) * 2006-11-08 2013-02-05 T2 Biosystems, Inc. NMR systems for in vivo detection of analytes
US9375495B2 (en) * 2007-04-12 2016-06-28 Industry-Academic Cooperation Foundation, Yonsei University Magnetic resonance imaging contrast agents comprising zinc-containing magnetic metal oxide nanoparticles
US20120003160A1 (en) * 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
US8421458B2 (en) 2007-09-28 2013-04-16 T2 Biosystems, Inc. NMR diagnostics by means of a plastic sample container
AU2008325088A1 (en) 2007-11-06 2009-05-14 T2 Biosystems, Inc. Small magnet and RF coil for magnetic resonance relaxometry
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
EP2277181B1 (fr) * 2008-04-16 2017-08-30 StemCell Technologies Inc. Particules magnétiques
EP2348976B1 (fr) 2008-10-29 2020-12-02 T2 Biosystems, Inc. Détection par rmn du temps de coagulation
US8840868B2 (en) 2009-02-04 2014-09-23 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using CR2-targeted nanoparticles
CA2756170C (fr) 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Vaccins glycoconjugues
MX2011009936A (es) 2009-03-25 2011-10-06 Pharmacosmos Holding As Un compuesto de oligosacarido de hierro estable.
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
CN103025314A (zh) 2010-05-26 2013-04-03 通用医疗公司 磁性纳米微粒
WO2011153331A2 (fr) 2010-06-02 2011-12-08 The General Hospital Corporation Conjugués de détection optiques pour détecter des espèces d'oxygène réactif et/ou d'azote réactif in vivo
CN102451185A (zh) 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
CA2815085C (fr) 2010-10-22 2022-06-21 T2 Biosystems, Inc. Systemes de rmn et procedes de detection rapide d'analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
CN102086232B (zh) * 2010-12-15 2012-05-23 吕辉 一种多糖铁的制备方法
CA2841484A1 (fr) 2011-07-13 2013-01-17 T2 Biosystems, Inc. Procedes de resonance magnetique nucleaire (rmn )pour surveiller la formation de caillots sanguins
WO2013021143A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
US10620205B2 (en) 2011-09-21 2020-04-14 T2 Biosystems, Inc. NMR methods for endotoxin analysis
US9958416B2 (en) 2011-11-23 2018-05-01 The General Hospital Corporation Analyte detection using magnetic hall effect
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
EP2647389A1 (fr) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Dispersion de nanoparticules magnétiques, sa préparation et diagnostic et utilisation thérapeutique
WO2013158281A1 (fr) 2012-04-20 2013-10-24 T2 Biosystems, Inc. Compositions et procédés de détection d'espèces de candida
WO2013187954A1 (fr) 2012-06-12 2013-12-19 The General Hospital Corporation Marquage magnétique de bactéries
WO2014004577A1 (fr) 2012-06-25 2014-01-03 The General Hospital Corporation Tri de particules au moyen de champs magnétiques à gradient élevé
US9675640B2 (en) * 2012-08-07 2017-06-13 Southwest Research Institute Magnetic calcium phosphate nanoparticles, applications and methods of preparation thereof
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
WO2014089346A1 (fr) 2012-12-07 2014-06-12 T2 Biosystems, Inc. Procédés de surveillance de formation de caillot solide
EP2968503B1 (fr) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anticorps antihepcidine et leurs utilisations
US9370202B2 (en) 2013-03-15 2016-06-21 LG Bionano, LLC Encapsulated metal ion nanoclusters
US10202577B2 (en) 2013-10-18 2019-02-12 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
US9566216B2 (en) 2013-11-18 2017-02-14 Southwest Research Institute Bone cements containing magnetic calcium phosphate nanoparticles
KR20150078375A (ko) 2013-12-30 2015-07-08 한화케미칼 주식회사 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물
WO2015108783A1 (fr) 2014-01-16 2015-07-23 The Brigham And Women's Hospital, Inc. Administration ciblée de médicaments immunorégulateurs
TWI689310B (zh) 2014-07-11 2020-04-01 巨生生醫股份有限公司 治療鐵缺乏症之方法
WO2016049036A1 (fr) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Anticorps anti-hepcidine humanisés et utilisations de ceux-ci
EP3215270B1 (fr) 2014-11-03 2020-05-27 The General Hospital Corporation Concentration de particules dans un dispositif microfluidique
CN105597105B (zh) * 2014-11-19 2020-03-10 连云港润众制药有限公司 一种菲立莫妥的制备方法
WO2016154362A1 (fr) 2015-03-23 2016-09-29 The Brigham And Women's Hospital, Inc. Nanoparticules tolérogéniques pour le traitement du diabète sucré
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
AU2017210033B2 (en) 2016-01-21 2022-09-29 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of bacteria
CN105708792A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁注射液及其制备方法
CN105708805A (zh) * 2016-01-28 2016-06-29 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁及其制备方法
CN105616372A (zh) * 2016-01-28 2016-06-01 山西普德药业股份有限公司 一种还原型羧烷基葡聚糖铁片剂
TR201703251A2 (tr) 2017-03-03 2017-07-21 Berna Buelbuel Kansizliğin transdermal yoldan tedavi̇si̇nde kullanilacak demi̇r oksi̇t nanokri̇stalleri̇ i̇çeren solüsyon
CN108403716B (zh) * 2018-06-25 2021-11-05 博瑞生物医药（苏州）股份有限公司 一种超顺磁氧化铁的制备方法
JP7588080B2 (ja) 2019-02-13 2024-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗末梢リンパ節アドレッシン抗体およびその使用
WO2025043086A1 (fr) 2023-08-22 2025-02-27 Navinta, Llc Procédé amélioré pour la préparation de férumoxytol solide
CA3280511A1 (en) 2024-07-18 2026-03-01 Malian Biologicals Gmbh Iron supplementation in affective disorders and/or post-traumatic stress disorder (ptsd) and/or serotonin-dependent diseases and iron supplementation in neurodevelopmental or psychiatric disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885393A (en) * 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US2862920A (en) * 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US2856398A (en) * 1956-06-15 1958-10-14 Ohio Commw Eng Co Carboxymethyl dextran-iron complexes
US3000872A (en) * 1956-06-15 1961-09-19 Ohio Commw Eng Co Preparation of carboxymethyl dextran-iron complexes
US2856366A (en) * 1956-07-30 1958-10-14 Ohio Commw Eng Co Stable alkaline metal solutions containing carboxymethyl dextran
US3151107A (en) * 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
GB1019513A (en) * 1961-08-07 1966-02-09 Chemicals Inc Iron dextran complexes
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
JP2806924B2 (ja) 1985-12-20 1998-09-30 ベーリングヴェルケ・アクチェンゲゼルシャフト 粒子分離方法
US5076950A (en) 1985-12-20 1991-12-31 Syntex (U.S.A.) Inc. Magnetic composition for particle separation
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5055288A (en) 1987-06-26 1991-10-08 Advanced Magnetics, Inc. Vascular magnetic imaging method and agent comprising biodegradeable superparamagnetic metal oxides
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
JP2726520B2 (ja) 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
WO1991009678A1 (fr) 1989-12-22 1991-07-11 Omni Quest Corporation Particules revetues d'un polymere organo-metallique utilisees dans des separations
GB9416767D0 (en) * 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
RU2147243C1 (ru) 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
EP0928809B1 (fr) 1996-08-30 2003-10-22 Meito Sangyo Kabushiki Kaisha Composite contenant un derive de polysaccharide et un oxyde metallique magnetique
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma

Also Published As

Publication number Publication date
US6599498B1 (en) 2003-07-29
DE60043188D1 (de) 2009-12-03
EP1169062B1 (fr) 2009-10-21
DK1169062T3 (da) 2010-01-25
ES2334555T3 (es) 2010-03-12
JP2011046752A (ja) 2011-03-10
US7553479B2 (en) 2009-06-30
ATE446108T1 (de) 2009-11-15
WO2000061191A9 (fr) 2001-06-21
JP2002541218A (ja) 2002-12-03
EP1169062A2 (fr) 2002-01-09
WO2000061191A3 (fr) 2001-05-25
PT1169062E (pt) 2009-12-17
CY1109527T1 (el) 2014-08-13
JP5064612B2 (ja) 2012-10-31
WO2000061191A2 (fr) 2000-10-19
US20030225033A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
DK1169062T3 (da) Varmestabile overtrukne kolloide jernoxider
AU2002355333A1 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy
IL159291A0 (en) Conjugates of macrocyclic metal complexes with biomolecules and the utilization thereof for producing agents for use in nmr diagnosis and radiodiagnosis and radiotherapy
JP2000121306A5 (fr)
PL356908A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU4064401A (en) Bile acids conjugates with metal ion chelates and the use thereof
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001275476A1 (en) An implantable medical device with aregarding coil magnetic shield
NL1013602A1 (nl) Het voorconditioneren van spins nabij een kernspinresonantiegebied.
AU1240801A (en) Coil structures and methods for generating magnetic fields
AU2003253688A1 (en) Magnetically shielded room with internal active magnetic field cancellation, and its use
DE60134274D1 (en) Complex enthaltend modafinil und cyclodextrin
ITMI20011708A0 (it) Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
AU4373499A (en) Use of drug-loaded nanoparticles for the treatment of cancers
WO1993012717A3 (fr) Milieux de contraste
WO2002013874A8 (fr) Utilisation de complexes metalliques contenant du perfluoroalkyle, en tant qu'agents de contraste dans le cadre de l'imagerie rm servant a representer des plaques, tumeurs et necroses
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU3221195A (en) Macrocyclic chelants, their chelates and uses thereof in the diagnostic field
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
GB2439857A (en) Shielded, asymmetric magnets for use in magnetic resonance imaging
AU2002241628A1 (en) Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
AU1660201A (en) Biglycan and related therapeutics and methods of use
MXPA02004069A (es) Uso de oxido nitrico para el tratamiento de construccion de vias aereas.
MY124005A (en) Composite magnetic body, and electromagnetic interference suppressing body using the same.